- Home
- FOXF vs ZLAB Comparison
FOXF vs ZLAB Comparison
Compare FOXF & ZLAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FOXF
- ZLAB
- Stock Information
- Founded
- FOXF 2007
- ZLAB 2013
- Country
- FOXF United States
- ZLAB China
- Employees
- FOXF N/A
- ZLAB N/A
- Industry
- FOXF Motor Vehicles
- ZLAB Biotechnology: Pharmaceutical Preparations
- Sector
- FOXF Consumer Discretionary
- ZLAB Health Care
- Exchange
- FOXF Nasdaq
- ZLAB Nasdaq
- Market Cap
- FOXF 1.6B
- ZLAB 1.8B
- IPO Year
- FOXF N/A
- ZLAB 2017
- Fundamental
- Price
- FOXF $37.00
- ZLAB $31.24
- Analyst Decision
- FOXF Hold
- ZLAB Strong Buy
- Analyst Count
- FOXF 6
- ZLAB 4
- Target Price
- FOXF $46.17
- ZLAB $52.50
- AVG Volume (30 Days)
- FOXF 293.5K
- ZLAB 976.3K
- Earning Date
- FOXF 10-31-2024
- ZLAB 11-12-2024
- Dividend Yield
- FOXF N/A
- ZLAB N/A
- EPS Growth
- FOXF N/A
- ZLAB N/A
- EPS
- FOXF 0.98
- ZLAB N/A
- Revenue
- FOXF $1,345,575,000.00
- ZLAB $322,711,000.00
- Revenue This Year
- FOXF N/A
- ZLAB $48.34
- Revenue Next Year
- FOXF $10.04
- ZLAB $47.12
- P/E Ratio
- FOXF $37.96
- ZLAB N/A
- Revenue Growth
- FOXF N/A
- ZLAB 28.16
- 52 Week Low
- FOXF $34.56
- ZLAB $13.48
- 52 Week High
- FOXF $86.14
- ZLAB $36.60
- Technical
- Relative Strength Index (RSI)
- FOXF 40.65
- ZLAB 70.41
- Support Level
- FOXF $36.65
- ZLAB $31.52
- Resistance Level
- FOXF $38.36
- ZLAB $36.60
- Average True Range (ATR)
- FOXF 1.35
- ZLAB 1.36
- MACD
- FOXF -0.21
- ZLAB 0.34
- Stochastic Oscillator
- FOXF 20.19
- ZLAB 58.60
About FOXF Fox Factory Holding Corp.
Fox Factory Holding Corp is a designer, manufacturer, and marketer of performance-defining products and systems used predominantly on bikes, Side-by-Sides, on-road vehicles with and without off-road capabilities, off-road vehicles and trucks, ATVs, snowmobiles, specialty vehicles and applications, motorcycles, and commercial trucks. Its business operates under the FOX, FOX RACING SHOX, and RACE FACE brands. Geographically, it derives a majority of revenue from North America and also has a presence in Asia, Europe, and the Rest of the World.
About ZLAB Zai Lab Limited
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-2306 for treatments across multiple solid tumor types including ovarian and certain types of breast and lung cancers; ZL-2401 which is an antibiotic in a new class of tetracycline derivatives; and ZL-2301 is an oral, small molecule which targets HCC.